Deliberative bodies have recommended additional protections for persons with dementia included in clinical trials. This survey of experienced dementia researchers revealed that 45 to 64% considered that specific ones of these recommendations would increase subject protection, and 40 to 86% considered they would make research less feasible. The real tradeoff between protection and difficulty in conducting research on devastating illnesses needs to be confronted when new regulations in this area are debated.
|Original language||English (US)|
|Number of pages||3|
|State||Published - Dec 23 2003|
ASJC Scopus subject areas
- Clinical Neurology